

Jean-François Delfraissy's biography

Born on 19th May 1948

Director of the "Infectious diseases" institute since April 21st, 2008

Degrees and qualifications

Doctor of Medicine

PhD in Sciences

University Professor – Hospital Practitioner

Professional experience

- | | |
|-----------|---|
| 1984-1987 | Secretary-General of the French Immunology Society |
| 1982-1986 | Member of Inserm's Specialized Scientific Commission 3 ("Infection and Immunity") |
| 1999-2003 | Chairman of the SIDACTION scientific council – Foundation for Medical Research. Member of the Board of Directors, Ensemble contre le Sida - SIDACTION |
| 1990-1994 | Medical advisor to the AIDS Mission, Hospitals Directorate, French Ministry for Health and Solidarity |
| 2001-2005 | Director of the Paris-Sud clinical research unit (URC) |
| July 2005 | Director of the French National Agency for Research on AIDS and viral hepatitis (ANRS) |

Recent publications

Lambotte O., Chaix M.L., Gubler B., Nasreddine N., Wallon C., Goujard C., Rouzioux C., Taoufik Y., Delfraissy J.F. *The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.* AIDS 2004, 18:1147-58.

- Lévy Y, Gahéry-Ségard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, Delfraissy J.F. *Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.* AIDS 2005; 19:279-86.

- Lambotte O, Khellaf M, Harmouche H, Bader-Meunier B, Manceron V, Goujard C, Delfraissy J.F. *Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome.* Medicine (Baltimore) 2006; 85:169-82.

- Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, Delfraissy J.F. *Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.* AIDS Res Hum Retroviruses 2007;23:1105-13.

- Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. *Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials.* J Infect Dis 2007; 196 Suppl 1:S46-51.

- Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C, Delfraissy JF, *Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study).* AIDS 2007;21:1043-1045.

- Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. *HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.* Proc Natl Acad Sci U S A 2007;104:6776-81.

- Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. *Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviralnaive HIV-infected patients.* AIDS 2008; 22:385-93.